CN103070877A - Vision care drug - Google Patents
Vision care drug Download PDFInfo
- Publication number
- CN103070877A CN103070877A CN201210573445XA CN201210573445A CN103070877A CN 103070877 A CN103070877 A CN 103070877A CN 201210573445X A CN201210573445X A CN 201210573445XA CN 201210573445 A CN201210573445 A CN 201210573445A CN 103070877 A CN103070877 A CN 103070877A
- Authority
- CN
- China
- Prior art keywords
- milligrams
- vision care
- vision
- milligram
- bata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a vision care drug that can improve ocular region blood circulation, protects retina from the harm of visible light and ultraviolet light, can effectively protect the eyes, prevents and reduces the generating of myopia, hyperopia and amblyopia, and is a vision care drug used conveniently. The drug comprises the following components in weigh: 1-75 mg of crocin, 1-50 mg of lutein, 1-50 mg of resveratrol, 1-50 mg of cryptoxanthin and 1-50 mg of Beta xanthophyll. The vision care drug can be applied to the field of vision care.
Description
Technical field
The present invention relates to a kind of medicine, relate in particular to a kind of vision care medicine.
Background technology
The decline of vision health is the current outstanding health problem that faces of Chinese Medicine health field.In the recent period, the control child myopia research project investigation of China, the U.S. and Australian cooperation development shows, China's myopia number is nearly 400,000,000, has reached 1.5 times of world average level 22%, and the near-sighted sickness rate of near-sighted colony occurred frequently---teenager colony is then up to 50% to 60%.China is one of country that near-sighted sickness rate is the highest in the world, myopia number the first in the world.A large amount of medical researches confirms that along with myopia degree is deepened, the incidence rate of various oculopathy will significantly increase, such as degeneration of macula, detachment of retina etc.At present, very limited for the means of each crowd's related preventive that comprises teenager and improvement, mainly be to do the modes such as eye exercises and employing diet control, and the effect that these modes can reach is very limited.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art; a kind of ocular blood circulation that improves is provided; the protection retina is avoided the injury of visible light ultraviolet light; can effectively protect eyes; the generation of prevention and minimizing myopia, hypermetropia, amblyopia, and vision care medicine easy to use.
The technical solution adopted in the present invention is: the present invention is a kind of vision care medicine, calculates by mass it and comprises following composition:
Crocin 1-75 milligram; Phylloxanthin 1-50 milligram; Resveratrol 1-50 milligram; Zeaxanthin 1-50 milligram; Bata-carotene 1-50 milligram.
[0005]Further, crocin is 75 milligrams; 50 milligrams of phylloxanthins; 50 milligrams of resveratrols; 50 milligrams of zeaxanthins; 50 milligrams of bata-carotenes.
Perhaps, crocin is 45 milligrams; 30 milligrams of phylloxanthins; 30 milligrams of resveratrols; 30 milligrams of zeaxanthins; 30 milligrams of bata-carotenes.
Or, 15 milligrams of crocins; 10 milligrams of phylloxanthins; 10 milligrams of resveratrols; 10 milligrams of zeaxanthins; 10 milligrams of bata-carotenes.
Described a kind of vision care medicine is made capsule, tablet, oral liquid or beverage.
The invention has the beneficial effects as follows: owing to the present invention includes crocin, phylloxanthin, resveratrol, zeaxanthin and bata-carotene, and these five kinds of compositions have following function:
Crocin has many-sided pharmacologically active, and the document of last decade has been found the unique protective effect of crocin to eye.A research is found, crocin can obviously increase rabbit retina and Choroid blood circulation, also help simultaneously recovery (the Xuan B. Effects of Crocin Analogs on Ocular Blood Flow and Retinal Function. J. ocul. Pharmacol. Th. of retinal function, 1999,15:143-152).And another studies show that, be exposed under the blue light, the retina rod cell demonstrates the dead trend of accelerating, and behind the adding crocin, the death of above cell is subject to obvious inhibition [Laabich A. Protective effect of crocin against blue light and white light-mediated photoreceptor cell death in bovine and primate retinal primary cell culture. Invest. Ophthalmol. Vis. Sci., 2006,47:3156-3163].
Phylloxanthin (lutein) is a kind of extensively being present in to contain oxygen carotenoid in vegetable, flowers, the fruit; mainly participate in consisting of macular pigment in the retina at human body; be distributed in macular area and whole retina; phylloxanthin is as antioxidant and photoprotection; can promote the regeneration of rhodopsin in the retina cell (Rhodopsin); laser high myopia and detachment of retina can be prevented, and vision, vision protection can be promoted.Ultraviolet in the sunlight and blue light enter eyes can produce a large amount of free radicals, causes cataract, and macular area is degenerated, even cancer.Ultraviolet generally can be filtered out by cornea and crystalline lens, but the through retina of the penetrable eyeball of blue light and macula lutea, the phylloxanthin in the macula lutea then can filter out blue light, avoids blue light to the infringement of eyes.Simultaneously, phylloxanthin can also the alleviating asthenopia symptom (blurred vision, eye are dry and astringent, ophthalmic bloated, ophthalmalgia, photophobia etc.).
Resveratrol is a kind of natural antioxidant, but blood viscosity lowering, anti-platelet clotting and vasodilation, keep unblocked blood flowing, but the generation of prophylaxis of cancer and development has atherosclerosis and coronary heart disease, ischemic heart desease, the preventive and therapeutic effect of hyperlipidemia.We study and find that resveratrol also has the effect of vision protection recently.
Zeaxanthin is a kind of natural fat-soluble pigment, can be used as light-filter, and eye metabolism and function are had a direct impact.Research confirms that zeaxanthin mainly concentrates on amphiblestroid macula lutea center, can remove because ultraviolet generation singlet molecular oxygen causes damage to eyes; can optionally carry out the macula lutea accumulation at eye; and macular pigment is provided, thus improve eye health status, vision is shielded.
The molecular structure of bata-carotene is equivalent to the vitamin A of 2 molecules, enter body after, through the effect of enzyme, wherein 50% becomes vitamin A in liver and mucous membrane of small intestine, the effect that has tonifying liver to make eye bright can be treated nyctalopia, vision protection is healthy.
Adopt the cells in vitro activity test method by the health medicine that the present invention is had above-mentioned five kinds of compositions; to cultivate the human retina cell survival rate as index; above-mentioned health medicine has been carried out Pharmacological Evaluation; the result shows that this medicine has the retina cell protective effect that significantly is better than single medicine.
So the present invention can improve the ocular blood circulation, the protection retina is avoided the injury of visible light ultraviolet light, can effectively protect eyes, the generation of prevention and minimizing myopia, hypermetropia, amblyopia, and easy to use.
Description of drawings
Fig. 1 is that the present invention is to the bar diagram of photic damage retina cell survival rate;
Fig. 2 is that the present invention is on the bar diagram of photic damage retina cell secretion of VEGF amount impact.
The specific embodiment
The invention provides a kind of vision care medicine, calculate by mass it and comprise following composition: crocin 1-1000 milligram; Phylloxanthin 1-75 milligram; Resveratrol 1-50 milligram; Zeaxanthin 1-50 milligram; Bata-carotene 1-50 milligram.
More specifically, can take off and state component: 75 milligrams of crocins; 50 milligrams of phylloxanthins; 50 milligrams of resveratrols; 50 milligrams of zeaxanthins; 50 milligrams of bata-carotenes.
Perhaps, crocin is 45 milligrams; 30 milligrams of phylloxanthins; 30 milligrams of resveratrols; 30 milligrams of zeaxanthins; 30 milligrams of bata-carotenes.
Or, 15 milligrams of crocins; 10 milligrams of phylloxanthins; 10 milligrams of resveratrols; 10 milligrams of zeaxanthins; 10 milligrams of bata-carotenes.
Certainly, can also get other weight according to the vision situation of human body, in this for example explanation that differs.The use of above component all is to calculate according to average daily use amount.
Behind above composition mix homogeneously, can be made into health food and the medicine of various dosage forms, for example make capsule, tablet, oral liquid or beverage.
Below provide specific embodiment explanation the present invention to the impact of vision.
The medication test of medicine of the present invention:
Cultivate Human RPE Cells in Vitro, adjusting intensity of illumination is at 2500 lx.Treat that retinal pigment epithelium in 96 orifice plates grows to 80% when merging state, is divided into following five groups.Normal group (NC): not illumination does not add medicine; Model control group (MC): illumination 24h does not add medicine; Three groups of chemoprophylaxis groups, institute adds in the medicine, the composition of crocin, phylloxanthin, resveratrol, zeaxanthin and bata-carotene is pressed the 1.5:1:1:1:1 proportioning, three groups dosage is followed successively by 15 μ g/mL, 1.5 μ g/mL, 0.15 μ g/mL, after adding respectively described medicine and pretreatment 24h before the illumination, illumination cultivation 24h.After the illumination, continue to cultivate 24h, then carry out immediately the detection of index.
(1) mtt assay is measured cell survival rate:
Above-mentioned each group is abandoned supernatant, and adding the whole mass concentration of MTT is the serum-free medium 200 μ L of 0.5mg/mL, and 37 ℃ are continued to cultivate, and stop behind the 4h cultivating.Carefully pick up the culture supernatant in the hole, every hole adds 150 μ L dimethyl sulfoxide, and vibration 5min fully dissolves the purple crystal thing.Measure the absorbance in each hole in 490nm wavelength place with microplate reader.Calculate cell survival rate according to formula (1):
Cell survival rate/%=(A sample 490nm/A contrasts 490nm) * 100 (1)
In the formula: A sample 490nm is that sample is at the absorbance at 490nm wavelength place; A contrast 490nm is that Normal group is at the absorbance at 490nm wavelength place.
Each organizes measurement result as shown in Figure 1.
The result of Fig. 1 shows: under the condition of illumination, the cell survival rate detail of three groups of chemoprophylaxis groups (3,4,5 groups) is higher than the cell survival rate of model control group (2 groups).
(2) detection of vascular endothelial cell growth factor (VEGF) expression:
Collect and respectively organize culture supernatant is measured VEGF in the centrifuge tube of 0.5mL content, and cell lysis is measured cell protein (BCA).Culture supernatant is got supernatant in the centrifugal 10min of 1500r/min, operates according to the explanation of the mensuration test kit of people VEGF and BCA.Read absorbance at microplate reader 450nm and 560nm wavelength place respectively, the drawing standard curve draws respectively mass concentration CVEGF and the protein content Cpro of corresponding VEGF.Calculate M according to formula (2)
VEGF(content of the protein concentration VEGF of unit):
M
VEGF/(pg/mg pro) = CVEGF/Cpro (2)
In the formula: CVEGF is the VEGF mass concentration that drawn by standard curve/(pg/mL); Cpro is the cell protein quality concentration that records of BCA test kit/(mg/mL).
Each organizes measurement result as shown in Figure 2.
The result of Fig. 2 shows: the retina cell secretion of VEGF amount of three groups of chemoprophylaxis groups (3,4,5 groups) the obviously retina cell secretion of VEGF amount than model control group (2 groups) is low.
The present invention can be applicable to the vision care field.
Claims (5)
1. a vision care medicine is characterized in that, calculates by mass it and comprises following composition:
Crocin 1-75 milligram; Phylloxanthin 1-50 milligram; Resveratrol 1-50 milligram;
Zeaxanthin 1-50 milligram; Bata-carotene 1-50 milligram.
2. a kind of vision care medicine according to claim 1 is characterized in that, calculates by mass it and comprises following composition:
75 milligrams of crocins; 50 milligrams of phylloxanthins; 50 milligrams of resveratrols;
50 milligrams of zeaxanthins; 50 milligrams of bata-carotenes.
3. a kind of vision care medicine according to claim 1 is characterized in that, calculates by mass it and comprises following composition:
45 milligrams of crocins; 30 milligrams of phylloxanthins; 30 milligrams of resveratrols;
30 milligrams of zeaxanthins; 30 milligrams of bata-carotenes.
4. a kind of vision care medicine according to claim 1 is characterized in that, calculates by mass it and comprises following composition:
15 milligrams of crocins; 10 milligrams of phylloxanthins; 10 milligrams of resveratrols;
10 milligrams of zeaxanthins; 10 milligrams of bata-carotenes.
5. according to claim 1 to 4 each described a kind of vision care medicines, it is characterized in that: described a kind of vision care medicine is made capsule, tablet, oral liquid or beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210573445XA CN103070877A (en) | 2012-12-26 | 2012-12-26 | Vision care drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210573445XA CN103070877A (en) | 2012-12-26 | 2012-12-26 | Vision care drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103070877A true CN103070877A (en) | 2013-05-01 |
Family
ID=48147724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210573445XA Pending CN103070877A (en) | 2012-12-26 | 2012-12-26 | Vision care drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103070877A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623670A (en) * | 2013-11-06 | 2015-05-20 | 高松 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses |
| WO2016042528A1 (en) * | 2014-09-19 | 2016-03-24 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of corneal dystrophies. |
| CN105687483A (en) * | 2016-03-09 | 2016-06-22 | 宁波君瑞生物科技有限公司 | Granular preparation with function of improving eyesight |
| CN105727293A (en) * | 2014-10-31 | 2016-07-06 | 中国医药大学 | Composition for treating and relieving myopia, and preparing method and use thereof |
| US10561697B2 (en) | 2014-03-28 | 2020-02-18 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481804A (en) * | 2002-12-17 | 2004-03-17 | 无锡杰西医药科技有限公司 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
-
2012
- 2012-12-26 CN CN201210573445XA patent/CN103070877A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481804A (en) * | 2002-12-17 | 2004-03-17 | 无锡杰西医药科技有限公司 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
Non-Patent Citations (3)
| Title |
|---|
| 无: "研究发现喝红葡萄酒可以防止视力退化", 《食品与发酵科技》, vol. 46, no. 158, 31 December 2010 (2010-12-31) * |
| 董京艳等: "促进视网膜神经节细胞轴突生长的中药筛选研究", 《生物物理学报》, no. 1, 31 December 2009 (2009-12-31) * |
| 陈素美: "西红花的药理作用", 《国外医药植物药分册》, vol. 21, no. 3, 31 December 2006 (2006-12-31) * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623670A (en) * | 2013-11-06 | 2015-05-20 | 高松 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses |
| US10561697B2 (en) | 2014-03-28 | 2020-02-18 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders |
| WO2016042528A1 (en) * | 2014-09-19 | 2016-03-24 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of corneal dystrophies. |
| US10092585B2 (en) | 2014-09-19 | 2018-10-09 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of corneal dystrophies |
| CN105727293A (en) * | 2014-10-31 | 2016-07-06 | 中国医药大学 | Composition for treating and relieving myopia, and preparing method and use thereof |
| CN105687483A (en) * | 2016-03-09 | 2016-06-22 | 宁波君瑞生物科技有限公司 | Granular preparation with function of improving eyesight |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| US9814695B2 (en) | Ophthalmic solutions for glaucoma and conjunctivitis treatment | |
| CN103735733B (en) | A kind of compound preparation containing lutein ester and preparation method thereof | |
| CN102225087A (en) | Xanthophyll compound preparation with powerful eye-protecting effect | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN103070877A (en) | Vision care drug | |
| CN103300373A (en) | Lutein and procyanidine composite soft capsule and preparation method thereof | |
| CN106038612A (en) | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof | |
| CN103860625A (en) | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof | |
| WO2018212152A1 (en) | Composition and functional food for preventing myopia | |
| KR20180105239A (en) | Composition containing a composition of xanthophylls and dried plants | |
| KR102427225B1 (en) | Pharmaceutical composition comprising sglt-2 inhibitor for preventing or treating diabetic opthalmopathy disease | |
| CN114129574A (en) | Application of steroid compound, composition containing steroid compound and preparation method of composition | |
| EP3949971B1 (en) | Use of luteolin-7-o-glucoside or luteolin-7-o-glucuronide in preparation of medicine for eye injuries | |
| CN103316032A (en) | A hydroxytyrosol composition and applications thereof | |
| CN103039968A (en) | Formula of eyesight protecting heath care product and preparation method thereof | |
| CN108324705A (en) | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and anthocyanidin | |
| CN101040893A (en) | Blueberry capsule for protecting vision and the preparing method | |
| CN102150860A (en) | Composition for easing visual fatigue and assisting in improving memory | |
| Mazzotta et al. | Riboflavin and the Cornea and Implications for Cataracts | |
| CN105983006A (en) | Composition for relieving visual fatigue and preparation method of composition | |
| CN114146075A (en) | Taurine external use medicine for treating myopia and its preparation method and use | |
| JP6502603B2 (en) | Ophthalmic composition and functional food | |
| CN111450054A (en) | Ophthalmic preparation containing caffeic acid ester, preparation method and application | |
| Chalioulias et al. | Anterior ischaemic optic neuropathy associated with dapsone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130501 |